Skip to content

Matthias E. Liechti

University Hospital of Basel, University of Basel

176 papers in the library · 10,050 citations · publishing 2000-2026

Papers

Sort Most recent Most cited

Designer drugs: mechanism of action and adverse effects

Archives of Toxicology April 1, 2020 Dino Luethi, Matthias E. Liechti 258 citations

Abstract Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer...

DOI: 10.1007/s00204-020-02693-7 (opens in new tab) Full text (opens in new tab) Pharmacology Designer drug Mechanism of action Adverse effect +6

Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland.

Drug and Alcohol Dependence 2020 Yasmin Schmid, Irene Scholz, Laura Mueller et al.

Concomitant use of cannabis and other psychoactive substances is common and it is often difficult to differentiate its acute effects from those of other substances. This study aimed to characterize the acute toxicity of cannabis with and without co-use of other substances. Retrospective analysis of cases presenting at the emergency departments of three large hospitals in Switzerland due to...

Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines

Frontiers in Pharmacology November 28, 2019 Karolina E. Kolaczynska, Dino Luethi, Daniel Trachsel et al. 24 citations

Background: 2,4,5-Trimethoxyamphetamine (TMA-2) is a potent psychedelic compound. Structurally related 4-alkyloxy-substituted 2,5-dimethoxyamphetamines and phenethylamine congeners (2C-O derivatives) have been described but their pharmacology is mostly undefined. Therefore, we examined receptor binding and activation profiles of these derivatives at monoamine receptors and transporters....

DOI: 10.3389/fphar.2019.01423 (opens in new tab) Serotonin 5-HT Receptor Pharmacology Intrinsic activity +4

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects

Neuropsychopharmacology November 16, 2019 Friederike Holze, Patrick Vizeli, Felix Müller et al. 250 citations

Abstract Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and d -amphetamine is a classic stimulant. All three substances are used recreationally. LSD and MDMA are being investigated as medications to assist psychotherapy, and d -amphetamine is used for the treatment of attention-deficit/hyperactivity disorder. All three...

No Influence of Dopamine System Gene Variations on Acute Effects of MDMA

Frontiers in Psychiatry October 24, 2019 Patrick Vizeli, Matthias E. Liechti 9 citations

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a recreational substance also investigated as medication for posttraumatic stress disorder. Dopamine (DA) system stimulation likely contributes to the acute mood effects of amphetamines, including MDMA. Genetic variants, such as single-nucleotide polymorphisms (SNPs), and polymorphic regions of the DA system genes may in part explain...

Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems

Journal of Psychopharmacology April 30, 2019 Dino Luethi, Karolina E. Kolaczynska, Melanie Walter et al. 39 citations

Background: Amphetamine analogs with a 3,4-methylenedioxy ring-substitution are among the most popular illicit drugs of abuse, exerting stimulant and entactogenic effects. Enzymatic N-demethylation or opening of the 3,4-methylenedioxy ring via O-demethylenation gives rise to metabolites that may be pharmacologically active. Indeed, previous studies in rats show that specific metabolites of...

Para-Halogenation Affects Monoamine Transporter Inhibition Properties and Hepatocellular Toxicity of Amphetamines and Methcathinones

Frontiers in Pharmacology April 24, 2019 Dino Luethi, Melanie Walter, Xun Zhou et al. 33 citations

Halogenated derivatives of amphetamine-type stimulants are appearing on the drug market, often with altered pharmacological profile and sometimes different legal status compared to the non-halogenated substances. The aim of the present study was to investigate the pharmacological profile and hepatocellular toxicity of para-halogenated amphetamines and cathinones. The potential of amphetamine,...

DOI: 10.3389/fphar.2019.00438 (opens in new tab) Serotonin Pharmacology Amphetamine Toxicity +5

Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects.

PLoS One April 13, 2019 Patrick Vizeli, Matthias E. Liechti 37 citations

Methylenedioxymethamphetamine (MDMA) increases oxytocin, empathy, and prosociality. Oxytocin plays a critical role in emotion processing and social behavior and has been shown to mediate the prosocial effects of MDMA in animals. Genetic variants, such as single-nucleotide polymorphisms (SNPs), of the oxytocin receptor (OXTR) may influence the emotional and social effects of MDMA in humans. The...

Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects

British Journal of Clinical Pharmacology March 19, 2019 Friederike Holze, Urs Duthaler, Patrick Vizeli et al. 72 citations

Aims The aim of the present study was to characterize the pharmacokinetics and exposure–subjective response relationship of a novel oral solution of lysergic acid diethylamide (LSD) that was developed for clinical use in research and patients. Method LSD (100 μg) was administered in 27 healthy subjects using a placebo‐controlled, double‐blind, cross‐over design. Plasma levels of LSD, nor‐LSD,...

DOI: 10.1111/bcp.13918 (opens in new tab) Pharmacokinetics Pharmacology

Role of Serotonin Transporter and Receptor Gene Variations in the Acute Effects of MDMA in Healthy Subjects

ACS Chemical Neuroscience December 27, 2018 Patrick Vizeli, Henriette E. Meyer zu Schwabedissen, Matthias E. Liechti 13 citations

Methylenedioxymethamphetamine (MDMA; ecstasy) is used recreationally and has been investigated as an adjunct to psychotherapy. Most acute effects of MDMA can be attributed to activation of the serotonin (5-hydroxytryptamine [5-HT]) system. Genetic variants, such as single-nucleotide polymorphisms (SNPs) and polymorphic regions in 5-HT system genes, may contribute to interindividual differences...

Neuroimaging of chronic MDMA (“ecstasy”) effects: A meta-analysis

Neuroscience & Biobehavioral Reviews November 12, 2018 Felix Müller, Raphael Brändle, Matthias E. Liechti et al. 52 citations

In this meta-analysis, we aimed to assess the evidence from neuroimaging studies for chronic alterations in the brains of MDMA users. The databases PubMed, Embase, and Web of Science were searched for studies published from inception to August 24, 2018, without any language restriction. Sixteen independent studies comprising 356 MDMA users and 311 controls were included. Of these, five studies...

Human Metabolome Changes after a Single Dose of 3,4-Methylenedioxymethamphetamine (MDMA) with Special Focus on Steroid Metabolism and Inflammation Processes

Journal of Proteome Research June 27, 2018 Martina I. Boxler, Gabriel L. Streun, Matthias E. Liechti et al. 23 citations

The intake of 3,4-methylenedioxymethamphetamine (MDMA) is known to increase several endogenous substances involved in steroid and inflammation pathways. Untargeted metabolomics screening approaches can determine biochemical changes after drug exposure and can reveal new pathways, which might be involved in the pharmacology and toxicology of a drug of abuse. We analyzed plasma samples from a...

The psychostimulant (±)-cis-4,4′-dimethylaminorex (4,4′-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters

Neuropharmacology June 23, 2018 Julian Maier, Felix P. Mayer, Dino Luethi et al. 24 citations

(±)-cis-4,4′-Dimethylaminorex (4,4′-DMAR) is a new psychoactive substance (NPS) that has been associated with 31 fatalities and other adverse events in Europe between June 2013 and February 2014. We used in vitro uptake inhibition and transporter release assays to determine the effects of 4,4′-DMAR on human high-affinity transporters for dopamine (DAT), norepinephrine (NET) and serotonin...

DOI: 10.1016/j.neuropharm.2018.06.018 (opens in new tab) Monoamine neurotransmitter Vesicular monoamine transporter Monoaminergic Pharmacology +7

Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics

The International Journal of Neuropsychopharmacology May 24, 2018 Dino Luethi, Matthias E. Liechti

The rapid assessment of in vitro pharmacological profiles of new psychoactive substances can help to predict psychoactive doses and effects in humans and facilitate the appropriate scheduling of new psychoactive substances.

DOI: 10.1093/ijnp/pyy047 (opens in new tab) Full text (opens in new tab) Pharmacology Monoamine neurotransmitter Dopamine transporter Serotonin transporter +5

Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs).

Neuropharmacology May 15, 2018 Dino Luethi, Daniel Trachsel, Marius C. Hoener et al. 50 citations

4-Thio-substituted phenethylamines (2C-T drugs) are potent psychedelics with poorly defined pharmacological properties. Because of their psychedelic effects, 2C-T drugs are sometimes sold as new psychoactive substances (NPSs). The aim of the present study was to characterize the monoamine receptor and transporter interaction profiles of a series of 2C-T drugs. We determined the binding...

DOI: 10.1016/j.neuropharm.2017.07.012 (opens in new tab) Full text (opens in new tab) New psychoactive substances Phenethylamines Psychedelics Powerful psychedelic effects +5

Pharmacological profile of mephedrone analogs and related new psychoactive substances.

Neuropharmacology May 15, 2018 Dino Luethi, Karolina E. Kolaczynska, Luca Docci et al.

Mephedrone is a synthetic cathinone and one of the most popular recreationally used new psychoactive substances. The aim of the present study was to characterize the in vitro pharmacology of novel analogs of mephedrone and related newly emerged designer stimulants. We determined norepinephrine, dopamine, and serotonin transporter inhibition potencies and monoamine release in...

DOI: 10.1016/j.neuropharm.2017.07.026 (opens in new tab) Full text (opens in new tab) Mephedrone Monoamine New psychoactive substances Receptors +1

Using in vitro norepinephrine transporter (NET) inhibition and 5‐HT 2 receptor binding data to predict psychoactive doses of novel psychoactive substances in humans

The FASEB Journal April 1, 2018 Matthias E. Liechti, Dino Luethi

Objective Novel psychoactive substances (NPS) or “bath salts” are increasingly sold over the Internet and used as substitutes for classic recreational substances. Previous studies showed that classic amphetamine‐type stimulants most potently act on the norepinephrine (NE) compared to the dopamine (DA) and serotonin (5‐HT) system and NE activation correlated with the subjective effects across...

Acute recreational drug toxicity

Medicine January 31, 2018 Evangelia Liakoni, Chris Yates, Alison M. Dines et al. 38 citations

The aim of the study was to compare self-reported and analytically confirmed substance use in cases of acute recreational drug toxicity.We performed a retrospective analysis of emergency department presentations of acute recreational drug toxicity over 2 years (October 2013 to September 2015) within the European Drug Emergencies Network Plus project.Among the 10,956 cases of acute recreational...

Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain.

Progress in Brain Research 2018 Felix Müller, Matthias E. Liechti, Undine E. Lang et al. 32 citations

The effects of hallucinogenic drugs on the human brain have been studied since the earliest days of neuroimaging in the 1990s. However, approaches are often hard to compare and results are heterogeneous. In this chapter, we summarize studies investigating the effects of hallucinogens on the resting brain, with a special emphasis on replicability and limitations. In previous studies,...

Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances.

Handbook of experimental pharmacology 2018 Linda D. Simmler, Matthias E. Liechti

New psychoactive substances (NPS) with amphetamine-, aminoindan-, and benzofuran basic chemical structures have recently emerged for recreational drug use. Detailed information about their psychotropic effects and health risks is often limited. At the same time, it emerged that the pharmacological profiles of these NPS resemble those of amphetamine or 3,4-methylenedioxymethamphetamine (MDMA)....

Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems

European Journal of Pharmacology December 8, 2017 Dino Luethi, Marius C. Hoener, Matthias E. Liechti 41 citations

Diclofensine, diphenidine, and methoxphenidine are new psychoactive substances (NPSs) that recently appeared on the illicit drug market. Pharmacological profiling of such newly emerged drugs is crucial for a better understanding of their psychotropic effects and toxicity. We therefore investigated the potential of these NPSs to inhibit the norepinephrine, dopamine, and serotonin transporters in...

DOI: 10.1016/j.ejphar.2017.12.012 (opens in new tab) Monoaminergic Monoamine neurotransmitter Pharmacology Norepinephrine transporter +5

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA

European Journal of Clinical Pharmacology December 2, 2017 Patrick Vizeli, Henriette E. Meyer zu Schwabedissen, Matthias E. Liechti 15 citations

Methylenedioxymethamphetamine (MDMA, ecstasy) is used recreationally and frequently leads to sympathomimetic toxicity. MDMA produces cardiovascular and subjective stimulant effects that were shown to partially depend on the norepinephrine transporter (NET)-mediated release of norepinephrine and stimulation of α 1 -adrenergic receptors. Genetic variants, such as single-nucleotide polymorphisms...

Acute Effects of Methylphenidate, Modafinil, and MDMA on Negative Emotion Processing

The International Journal of Neuropsychopharmacology November 22, 2017 André Schmidt, Felix Müller, Patrick C. Dolder et al. 25 citations

Background: Stimulants such as methylphenidate and modafinil are frequently used as cognitive enhancers in healthy people, whereas 3,4-methylenedioxymethamphetamine (ecstasy) is proposed to enhance mood and empathy in healthy subjects. However, comparative data on the effects of methylphenidate and modafinil on negative emotions in healthy subjects have been partially missing. The aim of this...

DOI: 10.1093/ijnp/pyx112 (opens in new tab) Full text (opens in new tab) MDMA Modafinil Methylphenidate Dextroamphetamine +1

Acute LSD effects on response inhibition neural networks

Psychological Medicine October 2, 2017 André Schmidt, Felix Müller, Claudia Lenz et al. 62 citations

Abstract Background Recent evidence shows that the serotonin 2A receptor (5-hydroxytryptamine2A receptor, 5-HT 2A R) is critically involved in the formation of visual hallucinations and cognitive impairments in lysergic acid diethylamide (LSD)-induced states and neuropsychiatric diseases. However, the interaction between 5-HT 2A R activation, cognitive impairments and visual hallucinations is...

DOI: 10.1017/s0033291717002914 (opens in new tab) Lysergic acid diethylamide Visual hallucination Parahippocampal gyrus Cingulate cortex +6

Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations

Acta Psychiatrica Scandinavica September 21, 2017 Felix Müller, Claudia Lenz, Patrick C. Dolder et al. 149 citations

Objective It has been proposed that the thalamocortical system is an important site of action of hallucinogenic drugs and an essential component of the neural correlates of consciousness. Hallucinogenic drugs such as LSD can be used to induce profoundly altered states of consciousness, and it is thus of interest to test the effects of these drugs on this system. Method 100 μg LSD was...